Illness Incorporated: Is A Healthy Population A Drag On Shareholder Returns?
Summary
Modern health care harbors a moral contradiction. Medicine saves lives, but the economy around sickness often grows when people remain chronically unwell. The vital signs measured in the clinic and the fragility of human cells carry the weight of complex decision and the limits of compassion. The clinician at the bedside sees a patient; the policymaker sees populations; the corporation sees markets; and the diplomat sees treaties. Each gaze is partial, but jointly they alter the conditions of life as surely as the work of a clinician or the discovery of a drug. Each reveals that health is never simply the absence of illness but the outcome of different interpretations and ambitions.
Selected Pull Quotes
“Health is never confined to the work of medicine. It is the threshold where science, politics, and commerce disclose their priorities.
“In healthcare, the clinician’s stethoscope can save a life; but it is the toolbox of a policy expert that can save a generation
“A health system is an index of national maturity and a mirror of its social contract. Investors may not list health in their public prospectus, but in practice, every clinic that treats malaria, every midwife who delivers safely, is a market signal as much as a public service
“Markets do not wither in the face of human fragility. What to households appears as misfortune or new pattern of disease, to investors reads as a new pattern of market incentive.
“Private equity does not enter the ward with a trolley. It enters with an abacus and a spreadsheet of returns
“Chronic health conditions script a lifetime contract between the infirm and the health value chain, where the profitable patient is no longer the one who recuperates, but the one who remains perpetually in treatment as a customer for life
“A vial of vaccine may weigh only grams, yet it carries the burden of alliances and enmities
“Intellectual property constructs invisible thresholds in health, deciding which lives gain access to therapies, under what terms, and at what price